Trial Profile

A prospective, multicentre, non-interventional, observational, post-authorisation safety study of ropeginterferon alfa-2b (250 micrograms or 500 micrograms solution for injection in pre-filled pen) in adult polycythaemia vera patients

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 17 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Dec 2025 According to an AOP Orphan Pharmaceuticals AG media release, data from the trial were presented at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA.
08 Jun 2023 New trial record
02 Jun 2023 According to AOP Health media release, this post-approval safety study (BESREMI-PASS) with a recruitment period of about three years has just completed patient recruitment.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com